Sosei Group

MiNA Therapeutics Limited is a clinical-stage biotechnology company based in London, United Kingdom, focused on the design and development of small activating RNA medicines aimed at restoring normal cellular function. Founded in 2008, the company is dedicated to harnessing gene activation mechanisms to create therapeutic solutions for cancer and other severe diseases. Its product pipeline includes MTL-CEBPA combined with Sorafenib for hepatocellular carcinoma and MTL-CEBPA paired with Pembrolizumab for advanced solid tumors. Through its innovative approach, MiNA Therapeutics aims to transform the treatment landscape, enabling healthcare professionals to effectively address challenging medical conditions.

JITSUBO aims to be a Peptide Lowest Cost Producer by continuously improving core technologies by incorporating all the latest technologies. JITSUBO company name is derived from "Chiba Jitsubo-san", a family business of Kazuhiro Chiba, a science and technology adviser and co-founder. Chiba Minorusan is a rare medicine that has been contributing to the health of people for over 500 years as a herbal medicine for women. The company named 'JITSUBO' from the desire to provide products that are useful for people's health through peptide drugs for a long time. We aim to be such a great mother-like company that continues to bring the results of technological innovation to the value of superior peptide drugs and continue to produce them in society.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Arakis Limited is a company dedicated to the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The firm specializes in researching cytokine and receptor-mediated mechanisms of disease, allowing it to identify and develop new clinical applications for established drugs and drug templates. By leveraging known medicines, Arakis aims to create performance-enhanced therapies, addressing unmet medical needs in its targeted therapeutic areas, which include inflammatory disease and pain management.